Ad-hoc | 31 August 2001 00:23

aap Implantate AG english

Ad-hoc-announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– aap continues to grow Sales up 83% / above-average increase in EBITDA / cash earnings up 300% First-half sales at aap Implantate AG were up markedly by roughly 83% to DM12.3m (previous: DM6.7m). In Germany, sales growth at 114% was way above the sectoral average. Export sales also sound an encouraging note. They were up 22%. A particularly gratifying trend was set by the bone cement and cementing techniques division. Its Versabond product, launched this year, has already achieved sales of roughly DM500 thousand. Total operating performance improved by roughly 79% to DM14.8m from DM8.2m. EBITDA not including stock options increased to DM1.2m (previous: minus DM129 thousand). Disregarding acquisition-related depreciations totaling roughly DM1.6m and stock options totaling DM812 thousand, first-half figures are as follows. The operating result improved by roughly 98% to minus DM21 thousand from minus DM856 thousand. The DVFA/SG group result for the review period was minus DM538 thousand (previous: minus DM544 thousand). Second-quarter DVFA/SG earnings per share were minus DM0.11 (previous: minus DM0.14). Cash earnings were up by roughly 300% on the year in the second quarter to roughly DM688 thousand from DM172 thousand. After acquisition-related depreciations and stock options the figures are as follows. The operating result was down to minus DM2.4m from minus DM856 thousand in the first half of 2000. DVFA/SG group result in the review period was minus DM2.0m (previous: minus DM544 thousand). DVFA/SG earnings per share totaled minus DM0.43 (previous: minus DM0.14). DVFA/SG cash earnings improved by roughly 370% on the year to about DM808 thousand from DM172 thousand. end of ad-hoc-announcement (c)DGAP 30.08.2001 Issuer’s information/explanatory remarks concerning this ad-hoc-announcement: Alongside the tie-up of production capacity for further development of the Biorigid Femur System (BFS) and Trauma Shoulder System (TSS), sales and marketing costs for the launch of the new products (BFS, TSS and Cerabone) affected the result. A further factor was intensive sales and marketing activities in the Middle East. One-off costs were incurred in connection with the integration of the Mebio/Coripharm group of companies. The first half was thus typical of the course of the business year at aap. Above-average sales and earnings growth in Germany and in export markets are anticipated in the second half of the year. ——————————————————————————– WKN: 506660; Index: Listed: Neuer Markt Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart 310023 Aug 01